Advertisement


Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

2024 ASCO Annual Meeting

Advertisement

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We're presenting the results of the CARTITUDE-4 focusing on the patients with one prior line of therapy, with emphasis on the patients with functional high-risk myeloma. Functional high-risk myeloma has long been recognized as those patients who have a progression within 18 months of the transplant or 18 months of the initial therapy. And that's a population that's particularly hard to treat, and is a population that has not been well represented in most randomized clinical trials. CARTITUDE-4 was a trial that compared cellular therapy, cell-to-cell and anti-BCMA autologous CAR-T cell therapy with a standard of care which was DARA-PD, or PVD in patients with one to three prior lines of therapy. And that was a very positive study that actually supported the approval in the U.S. and other jurisdictions of cell-to-cell as a therapy for patients with one to three lines of therapy as long as they were exposed to a proteasome inhibitor and exposed and refracted to lenalidomide. one of the question is I think with everybody's mind is, should we use this powerful therapy even in second line therapy with patients with one prior line? And this abstract helps to answer that. So we had in the overall study, we had 60 patients with one prior line of therapy on the cell-to-cell arm and 60 patients on the control arm. And of those 40 and 39 would meet criteria for functional high risk. And what we saw is for all patients with one prior line of therapy, cell-to-cell greatly reduced the risk of progression or death and led to a much higher rate of response, complete response and MRD negative response. And that effect was also seen. And if anything was magnified on the patient with functional high risk where cell-to-cell led to a more than 70% reduction in the risk of progression and death by leading to deeper and longer lasting responses. Of course, CAR-T cell and cell-to-cell has some unique toxicities such as cytokine release syndrome and ICANS, things that are on the back of everybody's mind as we consider those therapies. And what we saw is for this one prior line of therapy population, including the function of high risk, the rate of grade three or higher adverse events and severe adverse events was very similar between the two arms. When you look at those events of special interest CRS for example, that was very common. About 60% or more of the patients on the cell-to-cell arm developed those adverse events, but very rarely they were of high grade. There was one single case of high-grade CRS. The same thing for ICANs. There was less than 5% among the patients receiving cell-to-cell. And we had essentially one case of Parkinsonism, which is really consistent with the overall safety profile of cell-to-cell. So in general, this abstract give us some very tangible, useful data that patients with one line of therapy who have a lenalidomide refractor myeloma and proteasome inhibitor exposed myeloma do benefit from cell-to-cell over a standard of care. And that benefit is particularly important and robust among the patients with the functional high-risk disease.

Related Videos

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Gynecologic Cancers

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).

Advertisement

Advertisement




Advertisement